Drug Profile
Research programme: CNS disorder therapeutics - Alkermes
Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Rodin Therapeutics
- Developer Alkermes plc
- Class Antidementias; Antineoplastics; Small molecules
- Mechanism of Action Histone deacetylase and corepressor complex inhibitors; Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Frontotemporal dementia; Neurodegenerative disorders
Most Recent Events
- 28 Feb 2023 Preclinical development for Neurodegenerative disorders is ongoing USA (Alkermes pipeline, February 2023)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA
- 21 Apr 2021 Preclinical trials in Frontotemporal dementia in USA (unspecified route), prior to April 2021 (Alkermes pipeline, April 2021)